Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Content Wall Street Loves FIGS—Why Do Price Targets Predict Pullback?Reported by Jennifer Ryan Woods. Article Posted: 3/4/2026. 
In Brief - FIGS stock has surged nearly 260% over the past year, hitting a price not seen since shortly after its 2021 IPO.
- Q4 revenue topped $200 million—the company's best quarter ever—with scrubwear sales up 35% and international sales jumping 55%.
- Despite the rally and bullish analyst commentary, the consensus price target sits almost 30% below current levels.
After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has roared back to life, trading at a price it hasn't seen in nearly four years. The stock, now above $17, has surged almost 260% over the past year and climbed about 58% in the last month alone. The rally has been driven by strong earnings and a wave of bullish analyst commentary. Yet despite that momentum, the consensus 12-month price target is only $12.25—roughly 30% below the current price. That disconnect raises a key question: how much of FIGS' recovery is supported by fundamentals, and how much is momentum? A closer look at the company's history and recent results provides some clues. RAD Intel has grown from a $10M valuation at merger to $225M+, supported by recurring seven-figure enterprise contracts and 121% compounded annual growth over five years*.
The company has raised $60M+ from 15,000+ investors, including operators from Google, Meta, Amazon, and YouTube, alongside backing from multiple Fidelity funds. RAD was also selected by the Adobe Design Fund.
Shares remain available at $0.85 through an SEC-qualified Reg A+, though this pricing tier is scheduled to change tonight. Secure Your Shares Before Tonight's Price Adjustment Early investors saw a quick windfall after the May 2021 IPO, which priced at $22 per share and climbed to about $50 within a month. The COVID-19 pandemic initially boosted demand for medical apparel, but as the pandemic eased, shares reversed sharply and traded below $8 within a year. For much of the following period FIGS was range-bound in the single digits; after dipping below $4 in April 2025, the stock began another upward run. Earnings Momentum Sparks Rally Steady gains following positive Q1 and Q2 2025 earnings reports set the stage for a bigger move after the Q3 2025 results, released Nov. 6. The report showed stronger-than-expected revenue growth, solid demand across core product lines and healthy margins despite tariff headwinds. FIGS also issued an upbeat outlook, raising full‑year guidance for net revenue and adjusted EBITDA margins. Wall Street reacted positively: the stock jumped more than 30% over the following week and Zacks Research upgraded the shares to Strong Buy from Hold. The momentum continued after the Q4 2025 earnings report on Feb. 26. The company posted a 33% increase in quarterly revenue, its best quarter to date with sales topping $200 million. Management highlighted gains across the business during the earnings call—including a larger active customer base and higher average order values—and noted the company supplied Team USA's medical team during the Winter Olympics. Scrubwear, FIGS' core product, was a standout: sales in that segment, which accounted for over three-quarters of net revenue, rose 35%. International sales jumped 55%, helping the company deliver a record $630 million in net revenue for the year, up 14% year-over-year. Despite tariff pressures that weighed on gross margins, profitability was strong: full‑year adjusted EBITDA margin exceeded its target by more than 200 basis points. Analysts Applaud Earnings and Outlook FIGS provided an optimistic outlook for fiscal 2026, expecting net revenue to grow 10%–12% and targeting improved profitability. The company also plans to expand into new international markets, pursue growth opportunities across its businesses and continue its share buyback program. Analysts followed with a flurry of positive notes. Barclays upgraded to Strong Buy from Hold, KeyCorp moved to Overweight from Sector Weight (with a $17 price target), and Goldman Sachs adjusted its rating to Hold from Strong Sell. BTIG reiterated a Buy rating with a $15 target, and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets FIGS' earnings clearly spurred the push to four‑year highs. Shares began rising ahead of the Q4 release—jumping nearly 14% in the session before the report—and the rally accelerated after the results. The stock surged 24% on the first trading day after the announcement and added another 10% the following day. As of March 4, the stock was trading above $17, well above Morgan Stanley's $8 target issued in January and matching the highest target of $17 set by KeyCorp. The gap between enthusiastic analyst commentary and relatively low price targets suggests analysts appreciate FIGS' improving fundamentals but remain cautious about valuation. At current levels, the shares trade at a price-to-earnings ratio near 90, implying much of the company's expected growth is already priced in. There are few publicly traded direct competitors to FIGS; by contrast, lululemon athletica inc. (NASDAQ: LULU), a dominant lifestyle apparel player, trades at a P/E below 12. Bottom line: investors are applauding the turnaround, but skepticism persists about whether FIGS can sustain this run or if a pullback is possible.
| 
